First COVID-19 Variant Vaccine AZD2816 Phase II/III Trial Participants Vaccinated

27 June 2021 -- The first participants in a Phase II/III trial for the new COVID-19 variant vaccine AZD2816 were vaccinated today to assess its safety and immunogenicity in both previously vaccinated and unvaccinated adults. The trial will recruit...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials